{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:40:31Z","timestamp":1791520831394,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: The ratio of plasma aldosterone concentration to plasma renin activity (PRA) is considered the screening test of choice for primary aldosteronism. Uncertainty exists, however, regarding its diagnostic accuracy and the effects of antihypertensive drugs and dietary sodium balance on test characteristics.<\/jats:p>\n               <jats:p>Methods: We measured PRA and aldosterone in 118 white adults [71 men and 47 women; mean (SD) age, 51 (7) years] with previously diagnosed essential hypertension. Measurements were made while individuals were on antihypertensive drug therapy, after a 2-week drug-free period, after 4 days of dietary sodium loading, and after acute furosemide diuresis. We measured 24-h urine aldosterone excretion and PRA on the 4th day of dietary sodium loading to establish the diagnosis of primary aldosteronism. ROC curves were constructed for ratios measured under each clinical condition, and likelihood ratios were determined for individuals on or off antihypertensive drug therapy.<\/jats:p>\n               <jats:p>Results: Fifteen patients [13%; 95% confidence interval (CI), 7\u201320%] met the reference standard for primary aldosteronism. The mean (SD) areas under the ROC curves did not differ significantly across conditions of measurement [range, 0.80 (0.10) to 0.85 (0.04); P = 0.72]. When measured on and off antihypertensive drug therapy, the 95% CIs for the optimum cutpoint for the ratio overlapped. Point estimates of sensitivity on and off therapy were 73% (95% CI, 50\u201396%) and 87% (70\u2013100%), respectively, and specificities were 74% (65\u201383%) and 75% (66\u201384%). Under either condition, increased ratios were associated with 2.4- to 13-fold increases of posttest odds above pretest odds.<\/jats:p>\n               <jats:p>Conclusions: The aldosterone:PRA ratio provides only fair diagnostic accuracy in screening for primary aldosteronism, but concomitant antihypertensive drug therapy or acute variation in dietary sodium balance does not adversely affect test accuracy. Reporting of likelihood ratios associated with ranges of values of the aldosterone:PRA ratio, rather than use of a single \u201coptimum\u201d cutpoint, may enhance the usefulness of the test.<\/jats:p>","DOI":"10.1373\/clinchem.2004.041780","type":"journal-article","created":{"date-parts":[[2005,1,29]],"date-time":"2005-01-29T02:21:49Z","timestamp":1106965309000},"page":"386-394","source":"Crossref","is-referenced-by-count":177,"title":["Screening for Primary Aldosteronism in Essential Hypertension: Diagnostic Accuracy of the Ratio of Plasma Aldosterone Concentration to Plasma Renin Activity"],"prefix":"10.1093","volume":"51","author":[{"given":"Gary L","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T","family":"Turner","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,2,1]]},"reference":[{"key":"2020022800534875000_R1","doi-asserted-by":"crossref","unstructured":"Gordon RD, Ziezak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon\u2014twelve percent incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol1993;20:296-298.","DOI":"10.1111\/j.1440-1681.1993.tb01687.x"},{"key":"2020022800534875000_R2","doi-asserted-by":"crossref","unstructured":"Gordon RG, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol1994;21:315-318.","DOI":"10.1111\/j.1440-1681.1994.tb02519.x"},{"key":"2020022800534875000_R3","doi-asserted-by":"crossref","unstructured":"Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens2000;14:311-315.","DOI":"10.1038\/sj.jhh.1001013"},{"key":"2020022800534875000_R4","doi-asserted-by":"crossref","unstructured":"Loh KC, Koay ES, Khaw MC, Emmanual SC, Young WF, Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab2000;85:2854-2859.","DOI":"10.1210\/jc.85.8.2854"},{"key":"2020022800534875000_R5","doi-asserted-by":"crossref","unstructured":"Fardella C, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab2000;85:1863-1867.","DOI":"10.1210\/jcem.85.5.6596"},{"key":"2020022800534875000_R6","doi-asserted-by":"crossref","unstructured":"Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens2002;15:896-902.","DOI":"10.1016\/S0895-7061(02)02969-2"},{"key":"2020022800534875000_R7","doi-asserted-by":"crossref","unstructured":"Conn JW, Cohen ED, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable \u201cessential hypertension\u201d. JAMA1965;193:200-206.","DOI":"10.1001\/jama.1965.03090030022005"},{"key":"2020022800534875000_R8","doi-asserted-by":"crossref","unstructured":"Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after \u2018non-selective\u2019 screening of hypertensive patients. J Hypertens2003;21:2149-2157.","DOI":"10.1097\/00004872-200311000-00025"},{"key":"2020022800534875000_R9","doi-asserted-by":"crossref","unstructured":"Gordon RD. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens2004;22:251-255.","DOI":"10.1097\/00004872-200402000-00006"},{"key":"2020022800534875000_R10","doi-asserted-by":"crossref","unstructured":"Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Aust NZ J Med1976;6:131-135.","DOI":"10.1111\/j.1445-5994.1976.tb03306.x"},{"key":"2020022800534875000_R11","doi-asserted-by":"crossref","unstructured":"Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosterone producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med1981;141:1589-1593.","DOI":"10.1001\/archinte.141.12.1589"},{"key":"2020022800534875000_R12","doi-asserted-by":"crossref","unstructured":"Moneva MH, Gomez-Sanchez CE. Establishing a diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes2001;8:124-129.","DOI":"10.1097\/00060793-200106000-00004"},{"key":"2020022800534875000_R13","doi-asserted-by":"crossref","unstructured":"Young WF, Jr. Minireview: primary aldosteronism\u2014changing concepts in diagnosis and treatment. Endocrinology2003;144:2208-2213.","DOI":"10.1210\/en.2003-0279"},{"key":"2020022800534875000_R14","doi-asserted-by":"crossref","unstructured":"Montori VM, Young WF, Jr. Use of the plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am2002;31:619-632.","DOI":"10.1016\/S0889-8529(02)00013-0"},{"key":"2020022800534875000_R15","doi-asserted-by":"crossref","unstructured":"Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone\/renin activity ratio in primary aldosteronism. Hypertension2002;40:897-902.","DOI":"10.1161\/01.HYP.0000038478.59760.41"},{"key":"2020022800534875000_R16","doi-asserted-by":"crossref","unstructured":"Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein \u03b2(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension2001;37(2 Pt 2):739-743.","DOI":"10.1161\/01.HYP.37.2.739"},{"key":"2020022800534875000_R17","doi-asserted-by":"crossref","unstructured":"Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int2002;62:1718-1723.","DOI":"10.1046\/j.1523-1755.2002.00624.x"},{"key":"2020022800534875000_R18","doi-asserted-by":"crossref","unstructured":"Melton J. History of the Rochester Epidemiologic Project. Mayo Clin Proc1996;71:266-274.","DOI":"10.4065\/71.3.266"},{"key":"2020022800534875000_R19","doi-asserted-by":"crossref","unstructured":"Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textor SC, Gifford RW, et al. The changing clinical spectrum of primary aldosteronism. Am J Med1983;74:641-651.","DOI":"10.1016\/0002-9343(83)91022-7"},{"key":"2020022800534875000_R20","doi-asserted-by":"crossref","unstructured":"Sealey JE, Laragh JH. Searching out low renin patients: limitations of some commonly used methods. Am J Med1973;55:303-314.","DOI":"10.1016\/0002-9343(73)90132-0"},{"key":"2020022800534875000_R21","doi-asserted-by":"crossref","unstructured":"Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem1991;37(10 Pt 2):1811-1819.","DOI":"10.1093\/clinchem\/37.10.1811"},{"key":"2020022800534875000_R22","unstructured":"Sokal RR, Rohlf FJ. Biometry1981:98-127 WH Freeman and Company New York, NY. ."},{"key":"2020022800534875000_R23","doi-asserted-by":"crossref","unstructured":"DeLong ER, Delong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics1988;44:837-845.","DOI":"10.2307\/2531595"},{"key":"2020022800534875000_R24","doi-asserted-by":"crossref","unstructured":"Tanabe A, Natruse M, Takagi G, Tsuchiya K, Imaki T, Takano K. Variability in the renin\/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab2003;88:2489-2494.","DOI":"10.1210\/jc.2002-021476"},{"key":"2020022800534875000_R25","doi-asserted-by":"crossref","unstructured":"Kaplan NM, Kem DC, Holland OB, Kramer NJ, Higgins J, Gomez-Sanchez C. The intravenous furosemide test: a simple way to evaluate renin responsiveness. Ann Intern Med1976;84:639-645.","DOI":"10.7326\/0003-4819-84-6-639"},{"key":"2020022800534875000_R26","doi-asserted-by":"crossref","unstructured":"Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc2001;76:877-882.","DOI":"10.4065\/76.9.877"},{"key":"2020022800534875000_R27","doi-asserted-by":"crossref","unstructured":"Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone\/renin ratio. Clin Chem2002;48:1919-1923.","DOI":"10.1093\/clinchem\/48.11.1919"},{"key":"2020022800534875000_R28","doi-asserted-by":"crossref","unstructured":"McAreavey D, Murray GD, Lever AF, Robertson JIS. Similarity of idiopathic aldosteronism and essential hypertension. Hypertension1983;5:116-121.","DOI":"10.1161\/01.HYP.5.1.116"},{"key":"2020022800534875000_R29","doi-asserted-by":"crossref","unstructured":"Padfield PL. Primary aldosteronism, a common entity? The myth persists. J Hum Hypertens2002;16:159-162.","DOI":"10.1038\/sj.jhh.1001321"},{"key":"2020022800534875000_R30","doi-asserted-by":"crossref","unstructured":"Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens2004;22:863-869.","DOI":"10.1097\/00004872-200405000-00001"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/2\/386\/32681918\/clinchem0386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/2\/386\/32681918\/clinchem0386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:54:58Z","timestamp":1582851298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/51\/2\/386\/5629666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,2,1]]},"published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2004.041780","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,2,1]]},"published":{"date-parts":[[2005,2,1]]}}}